Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

6:18 AM ET 10-Q
Financial Results Js Beauty Land Network Technology Inc

Js Beauty Land Network Technology Q3 2026 Results: Net Loss of $66.5K, Loss Narrows

JS Beauty Land Network Technology Inc. reported zero revenue for the nine months ended September 30, 2026, as it currently has no substantive business operations. The company incurred a net loss of $190,981 and faces a working capital deficit of $262,084, leading to substantial doubt about its ability to continue as a going concern.

Key figure
Net loss $66.5K
6:17 AM ET 10-Q
Financial Results Estrella Immunopharma, Inc. ESLA

Estrella Immunopharma Q3 2026 Results: Net Loss of $7.38M, Loss Widens

Estrella Immunopharma reported a net loss of $11.98 million for the nine months ended September 30, 2026, compared to $12.45 million in the prior year period. The company's cash position decreased significantly to $92,458, while total stockholders' deficit widened to $13.97 million as research and development expenses remained the primary driver of operating costs.

Key figure
Net loss $7.38M
6:17 AM ET Form 4
Insider Selling Zymeworks Inc. ZYME

Zymeworks CSO Paul Andrew Moore Sells $1.04M of Stock

Paul Andrew Moore, CSO, sold 39,741 shares of Zymeworks Inc. at $26.04 to $26.14 a share (average $26.07) in 3 transactions, worth $1.04M in total on Nov 13, 2026. Shares held after the trade: 33,756 (-42.5%).

Value
$1.04M
Shares
39,741
Average price
$26.07
Role
CSO
Holding change
-42.5%
Trade date
Nov 13, 2026
6:16 AM ET 10-Q
Financial Results Powerus Corp PUSA

Powerus Q3 2026 Results: Net Loss of $342K, Loss Narrows

Powerus Corp reported a net loss of $1.64 million for the nine months ended September 30, 2026, an improvement from the $2.55 million loss in the prior year period. Total revenue grew to $2.62 million, driven primarily by golf operations, while the company significantly increased its asset base through a $20 million investment in a convertible note.

Key figure
Net loss $342K
6:16 AM ET 10-Q
Financial Results Healthier Choices Management Corp. HCMC

Healthier Choices Management Q3 2026 Results: Net Loss of $315K, Loss Narrows

Healthier Choices Management Corp. reported a significant decline in revenue to $76 for the quarter ended September 30, 2026, compared to $199 in the prior year, while narrowing its net loss to $315,418 from $2,076,113. The company's balance sheet shows a substantial decrease in total assets to $171,508 and a stockholders' deficit of $1,764,596 as it continues to focus on monetizing its intellectual property.

Key figure
Net loss $315K
6:16 AM ET 10-Q
Financial Results BioCorRx Inc. BICX

BioCorRx Q3 2026 Results: Net Loss of $797K, Loss Narrows

BioCorRx Inc. reported a net loss of $2,707,744 for the nine months ended September 30, 2026, compared to a loss of $2,921,916 in the prior year period. Total revenues decreased significantly to $126,690 from $527,047, while the company continues to rely heavily on grant income, which totaled $1,810,748 for the first nine months of 2026.

Key figure
Net loss $797K
6:16 AM ET 10-Q
Financial Results ClimateRock CLRCF

ClimateRock Q3 2026 Results: Net Loss of $307K, Loss Narrows

ClimateRock reported a net loss of $600,195 for the nine months ended September 30, 2026, compared to a loss of $844,755 in the prior year period. The company is a shell entity focused on a business combination, with total liabilities of $11,055,806 and a shareholders' deficit of $10,896,772 as of the reporting date.

Key figure
Net loss $307K
6:16 AM ET 10-Q
Financial Results Trutankless, Inc. TKLS

Trutankless Q3 2026 Results: Net Loss of $11.7M, Loss Widens

Trutankless, Inc. reported a significant increase in net sales to $1.84 million for the nine months ended September 30, 2026, compared to $748,491 in the prior year. However, the company experienced a substantial net loss of $17.02 million, driven by high consulting fees and a $7.49 million non-cash charge related to the change in fair value of stock payables liabilities.

Key figure
Net loss $11.7M
6:16 AM ET 10-Q
Financial Results DSwiss Inc DQWS

DSwiss Q3 2026 Results: Turns Profitable, Net Income $70.2K

For the nine months ended September 30, 2026, DSwiss Inc reported a net income of $71,939 on revenue of $1,482,275, a significant decrease in revenue compared to $2,464,144 in the prior year period. Despite the lower revenue, the company maintained profitability through improved gross margins and reduced cost of revenue, resulting in a basic and diluted net income per share of $0.0003.

Key figure
Net income $70.2K
6:16 AM ET 10-Q
Financial Results Quality Industrial Corp. QIND

Quality Industrial Q3 2026 Results: Net Loss of $74.3K, Loss Narrows

Quality Industrial Corp. reported a net income of $166,638 for the nine months ended September 30, 2026, a significant improvement from a net loss of $1,238,642 in the prior year period. Despite a slight decrease in nine-month revenue to $10.8 million, the company achieved operating income of $347,928 due to a substantial reduction in general and administrative expenses.

Key figure
Net loss $74.3K
6:16 AM ET 10-Q
Financial Results Outdoor Holding Co POWW ▶ Call

Outdoor Holding Q2 2026 Results: Net Income $2.3M, Up 63.6% YoY

Outdoor Holding Co reported net income attributable to common stock shareholders of $1.5 million for the quarter ended September 30, 2026, compared to $0.7 million in the prior year. Total net revenues increased to $13.7 million for the quarter, driven by growth in continuing operations, while the company continued its common stock repurchase program, acquiring over 3.4 million shares during the six-month period.

Key figure
Net income $2.3M · +63.6% YoY
6:16 AM ET 10-Q
Financial Results Cocrystal Pharma, Inc. COCP

Cocrystal Pharma Q3 2026 Results: Net Loss of $3.44M, Loss Widens

Cocrystal Pharma reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to $6.4 million in the prior year, driven by increased research and development expenses. The company raised substantial doubt about its ability to continue as a going concern, noting that its $4.9 million in cash and restricted cash is insufficient to fund operations for the next 12 months.

Key figure
Net loss $3.44M
6:16 AM ET 10-Q
Financial Results Odysight.ai Inc. ODYS

Odysight.ai Q3 2026 Results: Net Loss of $4.21M, Loss Narrows

Odysight.ai Inc. reported a total asset decrease to $27.1 million as of September 30, 2026, down from $29.0 million at the end of 2025, primarily driven by a reduction in cash and cash equivalents. The company's accumulated deficit grew to $76.7 million, reflecting ongoing operating losses, while shareholders' equity stood at $23.5 million.

Key figure
Net loss $4.21M
6:16 AM ET 10-Q
Financial Results Golden Star Resource Corp. GLNS

Golden Star Resource Q1 2026 Results: Net Loss of $17.4K, Loss Widens

Golden Star Resource Corp. is an exploration stage company with a working capital deficit of $965,666 and no revenue as of September 30, 2026. The company reported a net loss of $17,368 for the quarter, primarily driven by professional and office expenses, raising substantial doubt about its ability to continue as a going concern.

Key figure
Net loss $17.4K
6:16 AM ET Form 4
Insider Buying electroCore, Inc. ECOR

electroCore Insider Thomas J. Errico Buys $54.4K of Stock

Thomas J. Errico bought 10,000 shares of electroCore, Inc. at $5.44 a share, worth $54.4K in total on Nov 12, 2026. Shares held after the trade: 373,904 (+2.7%).

Value
$54.4K
Shares
10,000
Price
$5.44
Holding change
+2.7%
Trade date
Nov 12, 2026
6:16 AM ET Form 4
Insider Buying Amdocs Ltd DOX

Amdocs Director Eliahu Meir Gelman Buys $104K of Stock

Eliahu Meir Gelman, Director, bought 2,500 shares of Amdocs Ltd at $41.72 a share, worth $104K in total on Nov 9, 2026. Shares held after the trade: 353,446 (+0.7%).

Value
$104K
Shares
2,500
Price
$41.72
Role
Director
Holding change
+0.7%
Trade date
Nov 9, 2026
6:15 AM ET Form 4
Insider Buying Yum China Holdings, Inc. YUMC

Yum China Holdings Insider Alexander Dimitrief Buys $248K of Stock

Alexander Dimitrief bought 5,000 shares of Yum China Holdings, Inc. at $49.50 a share, worth $248K in total on Nov 13, 2026. Shares held after the trade: 8,691 (+135.5%).

Value
$248K
Shares
5,000
Price
$49.50
Holding change
+135.5%
Trade date
Nov 13, 2026
6:15 AM ET Form 4
Insider Buying Studio City International Holdings Ltd MSC

Studio City International Holdings Director Lawrence Yau Lung Ho Buys $30.9K of Stock

Lawrence Yau Lung Ho, Director, bought 111,832 shares of Studio City International Holdings Ltd at $0.2631 to $0.2868 a share (average $0.2763) in 2 transactions, worth $30.9K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 463,575,984 (+0.0%).

Value
$30.9K
Shares
111,832
Average price
$0.2763
Role
Director
Holding change
+0.0%
Trade date
Nov 12, 2026 to Nov 13, 2026
6:15 AM ET 8-K
Financial Results Quality Industrial Corp. QIND

Quality Industrial Financial Results

Quality Industrial Corp. reported its Q3 2026 financial results, showing a 3.6% revenue increase to $3.64 million and a return to operating income of $39,978. The company's net loss narrowed significantly to $31,512, driven by a 29.8% reduction in operating expenses and higher sales volumes in its UAE-based LPG distribution subsidiary, Al Shola Gas.

Term
Q3 2026
6:15 AM ET 8-K
Other 8-K Filing Oz Vision Inc. OZVN

Oz Vision Other 8-K Filing

OZ Vision Inc. announced that its audited financial statements for the fiscal years ended June 30, 2025, and June 30, 2026, should no longer be relied upon due to material misstatements regarding intangible assets. The company discovered that a $12.57 million Nevada State Athletic Commission license it had recorded was never validly transferred to the company and was non-transferable. The restatement is expected to eliminate approximately $13.1 million in assets, resulting in a total stockholders' deficit as of June 30, 2026.

Counterparty
Boladale Lawal & CO
6:14 AM ET 8-K
Loan & Debt Lithium Americas Corp. LAC

Lithium Americas $2.26B Debt Financing with United States Department of Energy

Lithium Americas entered into an omnibus amendment with the U.S. Department of Energy (DOE) regarding its $2.26 billion loan facility for the Thacker Pass project. The amendment updates the construction budget, project schedule, and equity funding requirements, including a commitment for $650 million in incremental contributions from the company's existing cash.

Value
$2.26B
Counterparty
United States Department of Energy
6:14 AM ET 8-K
Leadership Change Oscar Health, Inc. OSCR

Oscar Health Leadership Change

Oscar Health appointed Tomer Cohen, Eric Larsen, and Rajat Taneja to its Board of Directors, effective November 13, 2026, increasing the board size from eight to eleven. The new directors bring expertise from LinkedIn, Visa, and healthcare advisory roles, with specific appointments to the Audit, Compensation, and Nominating committees. All three appointees were determined to be independent under NYSE rules.

6:14 AM ET 8-K
Stock Buyback Zymeworks Inc. ZYME

Zymeworks Announces $200M Stock Buyback

Zymeworks authorized a new $200 million share repurchase program through 2028, following the completion of its initial $125 million program. The company expects to spend approximately $140 million under this new authorization to reduce share count and return capital to shareholders.

Value
$200M
Term
through 2028
6:14 AM ET 8-K
Other 8-K Filing Summit Therapeutics Inc. SMMT

Summit Therapeutics Other 8-K Filing

Summit Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for certain lung cancer patients. The FDA determined that the BLA cannot be approved in its current form because the progression-free survival benefit did not establish substantial evidence of effectiveness without a statistically significant improvement in overall survival.

Counterparty
FDA
6:14 AM ET 8-K
Product Launch Artificial Intelligence Technology Solutions Inc. AITX

Artificial Intelligence Technology Solutions Product Launch

Artificial Intelligence Technology Solutions' subsidiary, Robotic Assistance Devices (RAD), has launched a new Glass Break Detection AI analytic for its ROAMEO autonomous security patrol vehicle. The feature, developed over 17 months, allows the mobile robot to detect the sound of breaking glass and initiate automated investigation and evidence capture. This marks the fifth release of 15 engineering initiatives committed to by the company in July 2026.

6:14 AM ET 8-K
Shareholder Meeting Income Opportunity Realty Investors Inc IOR

Income Opportunity Realty Investors Shareholder Meeting

Income Opportunity Realty Investors held its Annual Meeting of Stockholders on November 11, 2026, where shareholders elected four directors to the board and ratified the appointment of Farmer, Fuqua & Huff, P.C. as the independent auditor for fiscal year 2026. Following the meeting, the board re-elected Henry A. Butler as Chairman and re-appointed Ted Munselle as Presiding Director.

6:14 AM ET 8-K
Financial Results AtlasClear Holdings, Inc. ATCH

AtlasClear Holdings Financial Results

AtlasClear Holdings, Inc. reported financial results for the fiscal quarter and nine months ended September 30, 2026, including the condensed consolidated financial statements of Autonomous Power Corporation. The company reported total revenues of $9.14 million and a net loss of $32.83 million for the nine-month period ended September 30, 2026.

Term
9 months
6:14 AM ET 8-K
M&A Deal Powerus Corp PUSA

Powerus M&A Deal with Autonomous Power Corporation

Powerus Corporation filed historical and pro forma financial statements related to its completed merger with Autonomous Power Corporation (Legacy Powerus). The merger, which closed on October 1, 2026, resulted in Legacy Powerus becoming a direct subsidiary of the company.

Counterparty
Autonomous Power Corporation
6:14 AM ET 8-K
Clinical Trial Data Aclaris Therapeutics, Inc. ACRS

Aclaris Therapeutics Clinical Trial Data

Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis failed to meet its primary and secondary endpoints. Despite robust target engagement and biomarker downregulation, the company will shift focus toward its oral ITK inhibitors and bispecific antibody ATI-052. The company also announced the initiation of a Phase 2b trial for modzatinib in lichen planus and plans to file an IND for ATI-9494 in Q4 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.